The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
Open accessAbstract
The use of antibody-based therapeutics has proven very promising for clinical applications in cancer patients, with multiple examples of antibodies and antibody-drug conjugates successfully applied for the treatment of solid tumors and lymphomas. Given reported recurrence rates, improvements are clearly still necessary. A major factor limiting the efficacy of antibody-targeted cancer therapies may be the incomplete penetration of the antibody or antibody-drug conjugate into the tumor. Incomplete tumor penetration also affects the outcome of molecular imaging, when using such targeting agents. From the injection site until they arrive inside the tumor, targeting molecules are faced with several barriers that impact intratumoral distribution. The primary means of antibody transport inside tumors is based on diffusion. The diffusive penetration inside the tumor is influenced by both antibody properties, such as size and binding affinity, as well as tumor properties, such as microenvironment, vascularization, and targeted antigen availability. Engineering smaller antibody fragments has shown to improve the rate of tumor uptake and intratumoral distribution. However, it is often accompanied by more rapid clearance from the body and in several cases also by inherent destabilization and reduction of the binding affinity of the antibody. In this perspective, we discuss different cancer targeting approaches based on antibodies or their fragments. We carefully consider how their size and binding properties influence their intratumoral uptake and distribution, and how this may affect cancer imaging and therapy of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476 · cited 1×
“In general, globular molecules smaller than ~40 kDa (hydrodynamic radii 2–6 nm) are rapidly removed from the body via renal filtration (34, 35).”
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179 · cited 1×
“Macromolecules larger than 40 kDa manage to circumvent renal excretion resulting in extended circulation time, increasing the chances of extravasation in the tumor interstitium (20, 21).”
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Soto, C., Sigurdsson, E. M., Morelli, L., Asok Kumar, R., Castaño, E. M., & Frangione, B. (1998) · Nature Medicine · doi:10.1038/nm0798-822 · Cited by 876
Michel, C. C., & Curry, F. E. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.3.703 · Cited by 811
Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain
Nord, K., Gunneriusson, E., Ringdahl, J., Ståhl, S., Uhlén, M., & Nygren, P.-Å. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-772 · Cited by 662
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Plückthun, A. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134654 · Cited by 575
Diffusion and Convection in Collagen Gels: Implications for Transport in the Tumor Interstitium
Ramanujan, S., Pluen, A., McKee, T. D., Brown, E. B., Boucher, Y., & Jain, R. K. (2002) · Biophysical Journal · doi:10.1016/s0006-3495(02)73933-7 · Cited by 552
Correlations between goldmann perimetry and maximal ERG response in retinitis pigmentosa
Vingolo, E. M., P., P., R., F., Pannarale, Giusti, C., & Rispoli, E. (1994) · IRIS Research product catalog (Sapienza University of Rome) · doi:10.1234/12345678 · Cited by 527
Peptide–drug conjugates as effective prodrug strategies for targeted delivery
Wang, Y., Cheetham, A. G., Angacian, G., Su, H., Xie, L., & Cui, H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.015 · Cited by 514
Odyssey of a cancer nanoparticle: From injection site to site of action
Nichols, J. W., & Bae, Y. H. (2012) · Nano Today · doi:10.1016/j.nantod.2012.10.010 · Cited by 364
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 356
Therapeutic antibody fragments with prolonged in vivo half-lives
Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., & King, D. J. (1999) · Nature Biotechnology · doi:10.1038/11717 · Cited by 350
Development trends for therapeutic antibody fragments
Nelson, A. L., & Reichert, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt0409-331 · Cited by 305
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Jain, R. K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00306-6 · Cited by 298
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & van Bergen en Henegouwen, P. M. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26145 · Cited by 284
Self-citationDesign considerations for nanotherapeutics in oncology
Stylianopoulos, T., & Jain, R. K. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.07.015 · Cited by 280
Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent
Dennis, M. S., Jin, H., Dugger, D., Yang, R., McFarland, L., Ogasawara, A., Williams, S., Cole, M. J., Ross, S., & Schwall, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2531 · Cited by 251
Adams, G. P., McCartney, J. E., Tai, M.-S., Oppermann, H., Huston, J. S., Stafford, W. F., Bookman, M. A., Fand, I., Houston, L. L., & Weiner, L. M. (1993) · PubMed · Cited by 248
Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls
Nakamura, H., Jun, F., & Maeda, H. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.955011 · Cited by 232
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., & Weiner, L. M. (1998) · PubMed · Cited by 230
Factors determining antibody distribution in tumors
THURBER, G., SCHMIDT, M., & WITTRUP, K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.11.004 · Cited by 223
Graff, C. P., & Wittrup, K. D. (2003) · PubMed · Cited by 205
Oliveira, S., van Dongen, G. A. M. S., Walsum, M. S.-V., Roovers, R. C., Stam, J. C., Mali, W., van Diest, P. J., & van Bergen en Henegouwen, P. M. P. (2012) · Molecular Imaging · doi:10.2310/7290.2011.00025 · Cited by 194
Self-citationHalf-life extended biotherapeutics
Kontermann, R. E. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1165661 · Cited by 191
van Driel, P. B. A. A., Boonstra, M. C., Slooter, M. D., Heukers, R., Stammes, M. A., Snoeks, T. J. A., de Bruijn, H. S., van Diest, P. J., Vahrmeijer, A. L., van Bergen en Henegouwen, P. M. P., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.014 · Cited by 166
Self-citationGainkam, L. O. T., Caveliers, V., Devoogdt, N., Vanhove, C., Xavier, C., Boerman, O. C., Muyldermans, S., Bossuyt, A. M., & Lahoutte, T. (2010) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.408 · Cited by 148
Davies, C. D. L., Berk, D. A., Pluen, A., & Jain, R. K. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600270 · Cited by 121
Hoefman, S., Ottevaere, I., Baumeister, J., & Sargentini‐Maier, M. L. (2015) · Antibodies · doi:10.3390/antib4030141 · Cited by 120
Goel, A., Colcher, D. M., Baranowska‐Kortylewicz, J., Augustine, S. C., Booth, B. J. M., Pavlínková, G., & Batra, S. K. (2000) · PubMed · Cited by 117
Thurber, G. M., & Wittrup, K. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3018 · Cited by 110
Optimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their Modulation
Jain, M., Venkatraman, G., & Batra, S. K. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2436 · Cited by 104
Grantab, R., & Tannock, I. F. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-214 · Cited by 94
Bispecific antibody platforms for cancer immunotherapy
Lameris, R., de Bruin, R. C. G., Schneiders, F. L., Henegouwen, P. M. P. V. B. E., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.08.003 · Cited by 90
Hopp, J., Hornig, N., Zettlitz, K. A., Schwarz, A. E., Fuss, N., Müller, D., & Kontermann, R. E. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq058 · Cited by 90
Andersen, J. T., Cameron, J., Plumridge, A., Evans, L. R., Sleep, D., & Sandlie, I. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463000 · Cited by 68
EGFR endocytosis requires its kinase activity and N-terminal transmembrane dimerization motif
Heukers, R., Vermeulen, J. F., Fereidouni, F., Bader, A. N., Voortman, J., Roovers, R. C., Gerritsen, H. C., & Henegouwen, P. M. P. V. B. E. (2013) · Journal of Cell Science · doi:10.1242/jcs.128611 · Cited by 63
Xiang, X., Phung, Y., Feng, M., Nagashima, K., Zhang, J., Broaddus, V. C., Hassan, R., FitzGerald, D., & Ho, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014640 · Cited by 51
Galgoczy, R., Pastor, I., Colom, A., Giménez, A., Mas, F., & Alcaraz, J. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.05.017 · Cited by 43
Dong, D., Xia, G., Li, Z., & Li, Z. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00265 · Cited by 24
Cantante, C., Lourenço, S., Morais, M., Leandro, J., Gano, L., Silva, N. E., Leandro, P., Serrano, M., Henriques, A. O., André, A., et al. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.05.017 · Cited by 23
Cited by
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Latest developments in molecular tracers for fluorescence image-guided cancer surgery
Hernot, S., van Manen, L., Debie, P., Mieog, J. S. D., & Vahrmeijer, A. L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30317-1 · Cited by 471
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
Marques, A. C., Costa, P. J., Velho, S., & Amaral, M. H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.035 · Cited by 349
Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
Filosofov, D., Kurakina, E., & Radchenko, V. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.12.001 · Cited by 341
Metadata
- Authors
- Xenaki, K. T., Oliveira, S., & van Bergen en Henegouwen, P. M. P.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-10-12
- Volume
- 8
- Pages
- 1287-1287
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2763302201
- Cited by
- 289
- References
- 59
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.